Parametric Portfolio Associates’s Nabriva Therapeutics plc Ordinary Shares Ireland NBRV Stock Holding History

Parametric Portfolio Associates’s Portfolio NBRV Stock Details NBRV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$11K	Sell	1,052 -591	-36%	-$7.18K	﹤0.01%	3667
2021 Q4	$25K	Hold	1,643	–	–	﹤0.01%	3619
2021 Q3	$49K	Hold	1,643	–	–	﹤0.01%	3577
2021 Q2	$55K	Buy	1,643 +972	+145%	+$36.2K	﹤0.01%	3532
2021 Q1	$28K	Hold	671	–	–	﹤0.01%	4038
2020 Q4	$41K	Buy	671 +59	+10%	+$6.39K	﹤0.01%	3957
2020 Q3	$81K	Buy	612 +446	+269%	+$74.5K	﹤0.01%	3822
2020 Q2	$28K	Sell	166 -15	-8%	-$2.5K	﹤0.01%	3887
2020 Q1	$26K	Sell	181 -30	-14%	-$9.18K	﹤0.01%	3882
2019 Q4	$70K	Hold	211	–	–	﹤0.01%	3904
2019 Q3	$105K	Buy	211 +2	+1%	+$1.13K	﹤0.01%	3827
2019 Q2	$127K	Buy	209 +135	+182%	+$82.8K	﹤0.01%	3810
2019 Q1	$45K	Buy	74 +33	+80%	+$18K	﹤0.01%	3891
2018 Q4	$15K	Buy	+41	New	+$22K	﹤0.01%	3891

Other funds holding NBRV

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

AICPI

ABG Innovation Capital Partners III Central, Hong Kong, Hong Kong $64.5K AUM 1.01% 1-Year Est. Return

VFA

Values First Advisors Gray, Tennessee $192M AUM 24.96% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Parametric Portfolio Associates's NBRV Position: Q1 2022 in Review

Parametric Portfolio Associates reduced its Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) stake by 36% in Q1 2022, selling an estimated $7.18K and leaving 1,052 shares worth $11K. The position accounts for ﹤0.01% of the portfolio, ranked #3667.

Parametric Portfolio Associates first reported a position in NBRV in Q4 2018 and has held it in 14 quarters since. The position peaked at $127K in Q2 2019. 29 funds tracked by Wall St. Rank hold NBRV as of Q1 2022.

Parametric Portfolio Associates held 1,052 shares of Nabriva Therapeutics plc Ordinary Shares Ireland worth $11K as of Q1 2022.
Parametric Portfolio Associates sold 591 Nabriva Therapeutics plc Ordinary Shares Ireland shares in Q1 2022, an estimated $7.18K.
Nabriva Therapeutics plc Ordinary Shares Ireland made up ﹤0.01% of Parametric Portfolio Associates's portfolio in Q1 2022, its #3667 holding.
Parametric Portfolio Associates first reported a position in Nabriva Therapeutics plc Ordinary Shares Ireland in Q4 2018 and has held it in 14 quarters since.
Parametric Portfolio Associates's Nabriva Therapeutics plc Ordinary Shares Ireland position peaked at $127K in Q2 2019.
29 funds tracked by Wall St. Rank held Nabriva Therapeutics plc Ordinary Shares Ireland as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.